We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+29.89%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.5B
AUM Growth
+$361M
Cap. Flow
+$95.2M
Cap. Flow %
6.35%
Top 10 Hldgs %
63.32%
Holding
74
New
17
Increased
21
Reduced
30
Closed
4

Top Buys

Rank Stock Value
1
GSK icon
GSK
GSK
+$33M
2
RVTY icon
Revvity
RVTY
+$31.9M
3
PFE icon
Pfizer
PFE
+$30.6M
4
VTRS icon
Viatris
VTRS
+$15.9M
5
INSP icon
Inspire Medical Systems
INSP
+$13.6M

Top Sells

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$35.6M
2
IMGN
Immunogen Inc
IMGN
+$22.2M
3
ARGX icon
argenx
ARGX
+$12.1M
4
ILMN icon
Illumina
ILMN
+$12.1M
5
KRYS icon
Krystal Biotech
KRYS
+$8.65M

Sector Composition

Rank Sector Weight
1 Healthcare 89.26%
2 Miscellaneous 10.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NTRA icon
1
Natera
NTRA
$47B
$163M 10.85%
1,778,051
-473,537
-21% -$35.6M
GSK icon
2
GSK
GSK
$102B
$162M 10.79%
3,771,994
+799,040
+27% +$33M
QQQ icon
3
PUT
Invesco QQQ Trust
QQQ
$489B
$145M 9.68%
326,800
+176,800
+118% +$75.8M
INSP icon
4
Inspire Medical Systems
INSP
$1.78B
$90.4M 6.03%
420,699
+69,583
+20% +$13.6M
TEVA icon
5
Teva Pharmaceuticals
TEVA
$42.5B
$85M 5.67%
6,025,169
-129,185
-2% -$1.63M
VERA icon
6
Vera Therapeutics
VERA
$2.46B
$78.6M 5.25%
1,823,781
-91,049
-5% -$3.24M
SNDX icon
7
Syndax Pharmaceuticals
SNDX
$1.74B
$74.6M 4.97%
3,133,113
-250,131
-7% -$5.58M
UTHR icon
8
United Therapeutics
UTHR
$22.1B
$57.7M 3.85%
251,135
+4,901
+2% +$1.11M
RVTY icon
9
Revvity
RVTY
$14.4B
$50.7M 3.38%
483,160
+300,101
+164% +$31.9M
TECH icon
10
Bio-Techne
TECH
$11.3B
$42.8M 2.85%
607,687
+142,380
+31% +$10.2M
HCA icon
11
HCA Healthcare
HCA
$90.5B
$34.6M 2.31%
103,821
-10,984
-10% -$3.36M
HQY icon
12
HealthEquity
HQY
$7.97B
$34.4M 2.29%
421,345
-73,574
-15% -$5.74M
PFE icon
13
Pfizer
PFE
$159B
$30.6M 2.04%
+1,102,042
New +$30.6M
CLDX icon
14
Celldex Therapeutics
CLDX
$3.07B
$29.8M 1.99%
711,115
-42,992
-6% -$1.77M
CYH icon
15
Community Health Systems
CYH
$413M
$27.9M 1.86%
7,980,641
+749,515
+10% +$2.53M
SWAV
16
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$26.2M 1.75%
80,555
+4,733
+6% +$1.16M
ARGX icon
17
argenx
ARGX
$64B
$21.5M 1.43%
54,518
-31,314
-36% -$12.1M
THC icon
18
Tenet Healthcare
THC
$21.5B
$18.5M 1.23%
175,631
-11,634
-6% -$1.05M
IONS icon
19
Ionis Pharmaceuticals
IONS
$10.1B
$16.3M 1.09%
376,438
+51,784
+16% +$2.47M
SPY icon
20
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$825B
$15.8M 1.06%
30,300
-89,700
-75% -$44.7M
VTRS icon
21
Viatris
VTRS
$18.8B
$15.7M 1.05%
+1,316,469
New +$15.9M
PCVX icon
22
Vaxcyte
PCVX
$8.9B
$13.5M 0.9%
197,331
-36,508
-16% -$2.53M
HUM icon
23
Humana
HUM
$46.3B
$12.3M 0.82%
35,532
+33,618
+1,756% +$12.7M
PTGX icon
24
Protagonist Therapeutics
PTGX
$9.34B
$11.9M 0.79%
411,478
-126,596
-24% -$3.44M
TARO
25
DELISTED
Taro Pharmaceutical Industries Ltd.
TARO
$11.2M 0.74%
263,541
+7,553
+3% +$318K
1
2 3

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q1 2024 Portfolio in Review

As of Q1 2024, Eversept Partners held 74 positions worth $1.5B, up 32% from $1.14B the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Eversept Partners deployed $95.2M of net new capital in Q1 2024, opening 17 new positions and adding to 21 existing holdings. Its largest new stake was Pfizer: 1,102,042 shares worth $30.6M.

By sector, the portfolio is most concentrated in Healthcare at 89% of assets, down from 90% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Natera, an estimated $35.6M trimmed.

  • Eversept Partners's largest Q1 2024 buy was Pfizer: 1,102,042 shares worth $30.6M.
  • Eversept Partners added most to GSK in Q1 2024, an estimated $33M increase.
  • Eversept Partners's biggest Q1 2024 reduction was Natera, cutting an estimated $35.6M.
  • Eversept Partners fully exited Immunogen Inc in Q1 2024, selling an estimated $22.2M.
  • Eversept Partners's ten largest holdings make up 63% of its $1.5B portfolio in Q1 2024.
  • Eversept Partners opened 17 new positions and closed 4 in Q1 2024.
  • Eversept Partners's portfolio value rose 32% quarter-over-quarter to $1.5B.

Based on Eversept Partners's 13F filing for Q1 2024, filed 15 May 2024.